Volume 15 Issue 3, September 2021

Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B.

The survival rate of liver failure patients may be improved by bioartificial liver which uses human hepatocyte-like cells transdifferentiated from umbilical cord fibroblasts, developed by Chinese company, Hexaell Biotech.

Lokon Pharma’s immunostimulatory gene therapy, delivered in oncolytic adenoviruses, are poised to enter pivotal trials for cancer. Biovian Oy is manufacturing Lokon’s immunotherapeutics for these trials and beyond.

Combining cell sorting technology with artificial intelligence, Japan-based ThinkCyte aims to discover novel high-value therapeutic cells, new functional genes, and novel drug candidates for itself and its partners worldwide.

With vast experience in cell-based therapies, Minaris Regenerative Medicine has become a trusted global partner for clinical and commercial manufacturing of cell therapies.

CyGenica Limited has developed a new class of engineered cell-penetrating protein as a drug delivery system, creating a drilling mechanism which can penetrate target cell membranes and safely deliver a range of cargoes including cancer drugs, antibiotics, gene therapy products and therapeutic nucleic acids.

Swiss-based Cell Receptor is discovering compounds aimed to tackle both cancer metastasis and autoimmune diseases.

MUVON Therapeutics has developed a patent-protected, GMP-compliant method for isolating and expanding muscle precursor cells that are injected into patients to promote regeneration of skeletal muscle, with an initial application in stress urinary incontinence.

Using CRISPR screening and single-cell RNA sequencing Aelian have created a high-throughput engine for target discovery in immuno-oncology.

NeuExcell Therapeutics is reprogramming glial cells into new neurons in situ to treat major neurodegenerative diseases.

Avalon GloboCare is a global leader in the development of transformative immune effector cell therapies. With 15 autologous and off-the-shelf cell therapy programs for a wide array of hematologic malignancies and solid tumors, Avalon is expanding horizons in cancer immunotherapy and cellular medicine.

TAGE enables targeted gene editing in the tumor microenvironment to enhance immuno-oncology responses.

Years of experience make Andelyn Biosciences the right manufacturing partner for those developing cell and gene therapies worldwide.

Potential game-changing Cell Squeeze technology opens up cell therapy to diverse cells and cargoes in immuno-oncology and beyond.

Combining single-cell genomics and bioinformatics, Decibel Therapeutics is developing precision gene therapies to treat disorders affecting the inner ear.

Actinium combines the precise targeting ability of monoclonal antibodies with the proven cancer-fighting power of radiation to develop innovative therapies for patients with cancers lacking effective treatment options.

Mustang Bio is developing next-generation CAR T and gene therapies for cancer and rare genetic diseases, with lead clinical programs in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and X-linked severe combined immunodeficiency.

With unmatched industry expertise, Dark Horse Consulting provides strategic and technical services to help clients realize their goals of bringing therapies to patients and commercialization. Those seeking services from Dark Horse Consulting range from biopharmaceutical companies to tools and tech providers to investment firms.

Recent deals involving bispecific antibodies illustrate the growing breadth of cancer immunotherapy applications for this platform.

Adrenomed AG is translating the concept of precision medicine to acute care with a biomarker-guided antibody therapy for sepsis and septic shock.

Ab Studio combines traditional approaches with computer-aided design to speed development of therapeutic antibodies.

With its innovative antibody discovery platform ADLib, Chiome Bioscience is nurturing a pipeline of antibody candidates ready for partnering.

Unparalleled success in antibody discovery and development.

Alloy Therapeutics, a biotechnology ecosystem company, is committed to providing affordable and non-exclusive access to a portfolio of foundational tools and services for the drug discovery community. Alloy’s lead platform is ATX-Gx, the world’s first royalty-free humanized mouse discovery platform.

ImmunoPrecise offers a comprehensive suite of solutions to rapidly deliver high-performing therapeutic antibodies.

Singh Biotechnology is developing novel camelid–derived single domain antibodies that target key intracellular molecular switches in cancer. The technology has therapeutic applications beyond cancer, and the company is seeking partners to advance its assets from preclinical to commercialization.

With a unique ownership structure and stable long-term funding, Biomed Valley Discoveries fuels a virtuous circle of investment, profit and research for the benefit of patients with unmet medical needs.

After an unusual year, M&A activity picked up again in the biopharma industry with a number of billion-dollar deals.

Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

Fast-tracking future health solutions.

Next-generation immuno-oncology targets continue to catalyze major deals, exemplified by the race to develop inhibitors of the immune checkpoint TIGIT.

Precision medicine is at the heart of immunotherapy, yet the development of new immunotherapies is hampered by the lack of predictive biomarkers, access to NGS testing, and large prospective trials. Strata Oncology is addressing these challenges through an integrated platform.

Driven by its small molecule libraries, biotech company Anticancer Bioscience has identified a line of oncology programs that could work as single agents or combination therapies.

By focusing on immunogenic cell death (ICD) as a complementary mechanism to existing cancer immunotherapy strategies, Phosplatin Therapeutics is building a global network of partnerships to help advance the application of its lead ICD inducer, PT-112, against a variety of cancers.

Pennsylvania-based Geneos Therapeutics is using its clinically validated GT-EPIC platform to generate cancer immunotherapies with high neoantigen payloads, and more.

Revitope is developing conditionally activated, T cell–engaging, bispecific antibodies containing dual tumor-specific antigens and split T cell–targeting paratopes that are unique in their high tolerability. The company is now focused on advancing its therapies to deliver safer and more efficacious therapies especially in solid cancer settings.

By harnessing its proprietary nanotechnology ‘pullulan nanogel’, United Immunity is creating a generation of novel immunotherapies for cancer and infectious diseases such as COVID-19.

Trans-Atlantic biopharmaceutical company, Immatics, is poised to unlock and deliver innovative T cell-based therapies to cancer patients by harnessing two proprietary technology platforms for its own pipeline, and for collaborations with world-leading partners.